Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Launch of new iPad research product for rapid cognitive assessment

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the launch of a new product in the Cantab Connect range. The product, Cantab Connect Research, will primarily be used by academic researchers requiring rapid, accurate and reproducible clinical measures of cognitive function in universities and research institutes around the world allowing them for the first time to work collaboratively across multiple study sites with Cantab Connect's cloud technology.

Cognitive research is a vital component in the drive to find treatments for neuropsychiatric and neurological diseases, which represent an immense and growing health, social and economic burden. Cantab Connect technology provides valid, reliable and replicable data with its highly validated touchscreen tests delivered on iPad devices which can be used by researchers who are not experts in cognition to get the results they need.

Historically, based on peer reviewed journals the market for cognitive research is estimated at $205.75m. The Company expects this market to grow based on the fact that research into mental health is increasing globally. In Alzheimer's disease alone over $600m is forecasted to be invested for research by UK and US government, charities and research organisations in 2015.

The technology underpinning Cantab products was first developed 30 years ago at the University of Cambridge by Professors Trevor Robbins and Barbara Sahakian to provide investigators with sensitive cognitive tasks and high quality data. To date, over 1,500 peer-reviewed papers have been published, and the technology is used in over 800 universities worldwide, with the number increasing each year.

Dr. Andrew Blackwell, Cambridge Cognition Chief Scientific Officer commented: 

"To date products have been focused on neuroscience applications and Cantab Connect Research is ideal for use in research projects on Alzheimer's disease and Mild Cognitive Impairment (MCI) due to Alzheimer's disease. However, as the measurement of brain function in non-central nervous system disorders, such as cardiovascular disease, becomes more common we believe researchers who are not experts in cognition will find Cantab Connect Research an invaluable tool both as a general assessment of cognitive function and as a measurement of cognitive effects in healthy volunteers."

Chief Executive Officer of Cambridge Cognition, Nick Kerton, Commented:

"We are delighted to announce the launch of a new cloud based product into the academic research market. As discussed in our Interim Results in September, the Company has taken a more proactive and structured approach to how we market our products to academic institutions and this launch demonstrates our commitment to growing this sector of our business."

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.